|
1
|
Giachelli CM, Liaw L, Murry CE, Schwartz
SM and Almeida M: Osteopontin expression in cardiovascular
diseases. Ann NY Acad Sci. 760:109–126. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Weber GF and Cantor H: The immunology of
Eta-1/osteopontin. Cytokine Growth Factor Rev. 7:241–248. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Denhardt DT and Noda M: Osteopontin
expression and function: role in bone remodeling. J Cell Biochem
Suppl. 30–31(S30–31): 92–102. 1998. View Article : Google Scholar
|
|
4
|
Sodek J, Ganss B and McKee MD:
Osteopontin. Crit Rev Oral Biol Med. 11:279–303. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Christensen B, Kazanecki CC, Petersen TE,
Rittling SR, Denhardt DT and Sørensen ES: Cell type-specific
post-translational modifications of mouse osteopontin are
associated with different adhesive properties. J Biol Chem.
282:19463–19472. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Christensen B, Nielsen MS, Haselmann KF,
Petersen TE and Sørensen ES: Post-translationally modified residues
of native human osteopontin are located in clusters: identification
of 36 phosphorylation and five O-glycosylation sites and their
biological implications. Biochem J. 390:285–292. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Christensen B, Petersen TE and Sørensen
ES: Post-translational modification and proteolytic processing of
urinary osteopontin. Biochem J. 411:53–61. 2008. View Article : Google Scholar
|
|
8
|
Denhardt DT and Guo X: Osteopontin: a
protein with diverse functions. FASEB J. 7:1475–1482.
1993.PubMed/NCBI
|
|
9
|
Cho HJ, Cho HJ and Kim HS: Osteopontin: a
multifunctional protein at the crossroads of inflammation,
atherosclerosis, and vascular calcification. Curr Atheroscler Rep.
11:206–213. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Coppola D, Szabo M, Boulware D, Muraca P,
Alsarraj M, Chambers AF and Yeatman TJ: Correlation of osteopontin
protein expression and pathological stage across a wide variety of
tumor histologies. Clin Cancer Res. 10:184–190. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rittling SR and Chambers AF: Role of
osteopontin in tumour progression. Br J Cancer. 90:1877–1881. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
El-Tanani MK, Campbell FC, Kurisetty V,
Jin D, McCann M and Rudland PS: The regulation and role of
osteopontin in malignant transformation and cancer. Cytokine Growth
Factor Rev. 17:463–474. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bellahcène A, Castronovo V, Ogbureke KU,
Fisher LW and Fedarko NS: Small integrin-binding ligand N-linked
glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat
Rev Cancer. 8:212–226. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Smith LL, Cheung HK, Ling LE, Chen J,
Sheppard D, Pytela R and Giachelli CM: Osteopontin N-terminal
domain contains a cryptic adhesive sequence recognized by
alpha9beta1 integrin. J Biol Chem. 271:28485–28491. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yokosaki Y, Matsuura N, Sasaki T, Murakami
I, Schneider H, Higashiyama S, Saitoh Y, Yamakido M, Taooka Y and
Sheppard D: The integrin alpha(9)beta(1) binds to a novel
recognition sequence (SVVYGLR) in the thrombin-cleaved
amino-terminal fragment of osteopontin. J Biol Chem.
274:36328–36334. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Scatena M, Liaw L and Giachelli CM:
Osteopontin: a multifunctional molecule regulating chronic
inflammation and vascular disease. Arterioscler Thromb Vasc Biol.
27:2302–2309. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sun BS, Li Y, Zhang ZF, You J and Wang CL:
Osteopontin combined with CD44v6, a novel prognostic biomarker in
non-small cell lung cancer undergoing curative resection. Ann
Thorac Surg. 96:1943–1951. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gao YL, Xing LQ, Ren TJ, Hou JF, Xue Q,
Liu C and Han YM: The expression of osteopontin in breast cancer
tissue and its relationship with 21ras and CD44V6 expression. Eur J
Gynaecol Oncol. 37:41–47. 2016.
|
|
19
|
Yang L, Shang X, Zhao X, Lin Y and Liu J:
Correlation study between OPN, CD44v6, MMP-9 and distant metastasis
in laryngeal squamous cell carcinoma. Lin Chung Er Bi Yan Hou Tou
Jing Wai Ke Za Zhi. 26:989–992. 2012.In Chinese.
|
|
20
|
Kim JS, Bashir MM and Werth VP: Gottron's
papules exhibit dermal accumulation of CD44 variant 7 (CD44v7) and
its binding partner osteopontin: a unique molecular signature. J
Invest Dermatol. 132:1825–1832. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Allan AL, George R, Vantyghem SA, Lee MW,
Hodgson NC, Engel CJ, Holliday RL, Girvan DP, Scott LA, Postenka
CO, et al: Role of the integrin-binding protein osteopontin in
lymphatic metastasis of breast cancer. Am J Pathol. 169:233–246.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Courter D, Cao H, Kwok S, Kong C, Banh A,
Kuo P, Bouley DM, Vice C, Brustugun OT and Denko NC: The RGD domain
of human osteopontin promotes tumor growth and metastasis through
activation of survival pathways. PLoS One. 5:e96332010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cui R, Takahashi F, Ohashi R, Gu T,
Yoshioka M, Nishio K, Ohe Y, Tominaga S, Takagi Y, Sasaki S, et al:
Abrogation of the interaction between osteopontin and alphavbeta3
integrin reduces tumor growth of human lung cancer cells in mice.
Lung Cancer. 57:302–310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu CM, Chen PC, Li TM, Fong YC and Tang
CH: Si-Wu-tang extract stimulates bone formation through
I3K/Akt/NF-κB signaling pathways in osteoblasts. BMC Complement
Altern Med. 13:2772013. View Article : Google Scholar
|
|
25
|
Wang Y, Yan W, Lu X, Qian C, Zhang J, Li
P, Shi L, Zhao P, Fu Z, Pu P, et al: Overexpression of osteopontin
induces angiogenesis of endothelial progenitor cells via the
avβ3/I3K/AKT/eNOS/NO signaling pathway in glioma cells. Eur J Cell
Biol. 90:642–648. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ogata T, Ueyama T, Nomura T, Asada S,
Tagawa M, Nakamura T, Takahashi T, Matsubara H and Oh H:
Osteopontin is a myosphere-derived secretory molecule that promotes
angiogenic progenitor cell proliferation through the
phosphoinositide 3-kinase/Akt pathway. Biochem Biophys Res Commun.
359:341–347. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen RX, Xia YH, Xue TC, Zhang H and Ye
SL: Down-regulation of osteopontin inhibits metastasis of
hepatocellular carcinoma cells via a mechanism involving MMP-2 and
uPA. Oncol Rep. 25:803–808. 2011.
|
|
28
|
Mi Z, Guo H, Wai PY, Gao C and Kuo PC:
Integrin-linked kinase regulates osteopontin-dependent MMP-2 and
uPA expression to convey metastatic function in murine mammary
epithelial cancer cells. Carcinogenesis. 27:1134–1145. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tuck AB, Hota C and Chambers AF:
Osteopontin(OPN)-induced increase in human mammary epithelial cell
invasiveness is urokinase (uPA)-dependent. Breast Cancer Res Treat.
70:197–204. 2001. View Article : Google Scholar
|
|
30
|
Kerenidi T, Kazakou AP, Lada M, Tsilioni
I, Daniil Z and Gourgoulianis KI: Clinical significance of
circulating osteopontin levels in patients with lung cancer and
correlation with VEGF and MMP-9. Cancer Invest. 34:385–392. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Babarović E, Valković T, Budisavljević I,
Balen I, Štifter S, Duletić-Načinović A, Lučin K and Jonjić N: The
expression of osteopontin and vascular endothelial growth factor in
correlation with angiogenesis in monoclonal gammopathy of
undetermined significance and multiple myeloma. Pathol Res Pract.
212:509–516. 2016. View Article : Google Scholar
|
|
32
|
Lin Q, Guo L, Lin G, Chen Z, Chen T, Lin
J, Zhang B and Gu X: Clinical and prognostic significance of OPN
and VEGF expression in patients with non-small-cell lung cancer.
Cancer Epidemiol. 39:539–544. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Terpos E, Kiagia M, Karapanagiotou EM,
Charpidou A, Dilana KD, Nasothimiou E, Harrington KJ, Polyzos A and
Syrigos KN: The clinical significance of serum markers of bone
turnover in NSCLC patients: surveillance, management and prognostic
implications. Anticancer Res. 29:1651–1657. 2009.PubMed/NCBI
|
|
34
|
Hsieh IS, Huang WH, Liou HC, Chuang WJ,
Yang RS and Fu WM: Upregulation of drug transporter expression by
osteopontin in prostate cancer cells. Mol Pharmacol. 83:968–977.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Anborgh PH, Caria LB, Chambers AF, Tuck
AB, Stitt LW and Brackstone M: Role of plasma osteopontin as a
biomarker in locally advanced breast cancer. Am J Transl Res.
7:723–732. 2015.PubMed/NCBI
|
|
36
|
Friedmann-Morvinski D, Bhargava V, Gupta
S, Verma IM and Subramaniam S: Identification of therapeutic
targets for glioblastoma by network analysis. Oncogene. 35:608–620.
2016. View Article : Google Scholar
|
|
37
|
Güttler A, Giebler M, Cuno P, Wichmann H,
Keßler J, Ostheimer C, Söling A, Strauss C, Illert J, Kappler M, et
al: Osteopontin and splice variant expression level in human
malignant glioma: radiobiologic effects and prognosis after
radiotherapy. Radiother Oncol. 108:535–540. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Etiz D, Ataizi FC, Bayman E, Akcay M,
Acikalin MF, Colak E and Ciftci E: Prognostic value of osteopontin
in patients treated with primary radiotherapy for head and neck
cancer. Asian Pac J Cancer Prev. 14:5175–5178. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Imano M, Satou T, Itoh T, Sakai K,
Ishimaru E, Yasuda A, Peng YF, Shinkai M, Akai F, Yasuda T, et al:
Immunohistochemical expression of osteopontin in gastric cancer. J
Gastrointest Surg. 13:1577–1582. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Higashiyama M, Ito T, Tanaka E and Shimada
Y: Prognostic significance of osteopontin expression in human
gastric carcinoma. Ann Surg Oncol. 14:3419–3427. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ng L, Wan TM, Lam CS, Chow AK, Wong SK,
Man JH, Li HS, Cheng NS, Pak RC, Cheung AH, et al: Post-operative
plasma osteopontin predicts distant metastasis in human colorectal
cancer. PLoS One. 10:e01262192015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ng L, Wan T, Chow A, Iyer D, Man J, Chen
G, Yau TC, Lo O, Foo CC, Poon JT, et al: Osteopontin overexpression
induced tumor progression and chemoresistance to oxaliplatin
through induction of stem-like properties in human colorectal
cancer. Stem Cells Int. 2015:2478922015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Poruk KE, Firpo MA, Scaife CL, Adler DG,
Emerson LL, Boucher KM and Mulvihill SJ: Serum osteopontin and
tissue inhibitor of metalloproteinase 1 as diagnostic and
prognostic biomarkers for pancreatic adenocarcinoma. Pancreas.
42:193–197. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Koopmann J, Fedarko NS, Jain A, Maitra A,
Iacobuzio-Donahue C, Rahman A, Hruban RH, Yeo CJ and Goggins M:
Evaluation of osteopontin as biomarker for pancreatic
adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 13:487–491.
2004.PubMed/NCBI
|
|
45
|
Liu G, Fan X, Tang M, Chen R, Wang H, Jia
R, Zhou X, Jing W, Wang H, Yang Y, et al: Osteopontin induces
autophagy to promote chemo-resistance in human hepatocellular
carcinoma cells. Cancer Lett. 383:171–182. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gimba ER and Tilli TM: Human osteopontin
splicing isoforms: known roles, potential clinical applications and
activated signaling pathways. Cancer Lett. 331:11–17. 2013.
View Article : Google Scholar
|
|
47
|
Salem M, Atti SA, Raziky ME, Darweesh SK
and Sharkawy ME: Clinical significance of plasma osteopontin level
as a biomarker of hepatocellular carcinoma. Gastroenterology Res.
6:191–199. 2013.PubMed/NCBI
|
|
48
|
Xu ST, Guo C, Ding X, Fan WJ, Zhang FH, Xu
WL and Ma YC: Role of osteopontin in the regulation of human
bladder cancer proliferation and migration in T24 cells. Mol Med
Rep. 11:3701–3707. 2015.PubMed/NCBI
|
|
49
|
Moszynski R, Szubert S, Szpurek D,
Michalak S and Sajdak S: Role of osteopontin in differential
diagnosis of ovarian tumors. J Obstet Gynaecol Res. 39:1518–1525.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Nakae M, Iwamoto I, Fujino T, Maehata Y,
Togami S, Yoshinaga M and Douchi T: Preoperative plasma osteopontin
level as a biomarker complementary to carbohydrate antigen 125 in
predicting ovarian cancer. J Obstet Gynaecol Res. 32:309–314. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Subramani VN, Narasimhan M, Thiyagarajan
M, Munuswamy BD and Jayamani L: Expression of osteopontin in oral
squamous cell carcinoma and its surgical margins-an
immunohistochemical study. J Clin Diagn Res. 9:ZC66–ZC69.
2015.PubMed/NCBI
|
|
52
|
Kiss T, Ecsedi S, Vizkeleti L, Koroknai V,
Emri G, Kovács N, Adany R and Balazs M: The role of osteopontin
expression in melanoma progression. Tumour Biol. 36:7841–7847.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Blasberg JD, Pass HI, Goparaju CM, Flores
RM, Lee S and Donington JS: Reduction of elevated plasma
osteopontin levels with resection of non-small-cell lung cancer. J
Clin Oncol. 28:936–941. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zduniak K, Ziolkowski P, Ahlin C, Agrawal
A, Agrawal S, Blomqvist C, Fjällskog ML and Weber GF: Nuclear
osteopontin-c is a prognostic breast cancer marker. Br J Cancer.
112:729–738. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ortiz-Martínez F, Perez-Balaguer A,
Ciprián D, Andrés L, Ponce J, Adrover E, Sánchez-Payá J, Aranda FI,
Lerma E and Peiró G: Association of increased osteopontin and
splice variant-c mRNA expression with HER2 and
triple-negative/basal-like breast carcinomas subtypes and
recurrence. Hum Pathol. 45:504–512. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Sun J, Feng A, Chen S, Zhang Y, Xie Q,
Yang M, Shao Q, Liu J, Yang Q, Kong B, et al: Osteopontin splice
variants expressed by breast tumors regulate monocyte activation
via MCP-1 and TGF-β1. Cell Mol Immunol. 10:176–182. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Pang H, Lu H, Song H, Meng Q, Zhao Y, Liu
N, Lan F, Liu Y, Yan S, Dong X, et al: Prognostic values of
osteopontin-c, E-cadherin and β-catenin in breast cancer. Cancer
Epidemiol. 37:985–992. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Patani N, Jouhra F, Jiang W and Mokbel K:
Osteopontin expression profiles predict pathological and clinical
outcome in breast cancer. Anticancer Res. 28:4105–4110. 2008.
|
|
59
|
Sun SJ, Wu CC, Sheu GT, Chang HY, Chen MY,
Lin YY, Chuang CY, Hsu SL and Chang JT: Integrin β3 and CD44 levels
determine the effects of the OPN-a splicing variant on lung cancer
cell growth. Oncotarget. 7:55572–55584. 2016.PubMed/NCBI
|
|
60
|
Zhao B, Sun T, Meng F, Qu A, Li C, Shen H,
Jin Y and Li W: Osteopontin as a potential biomarker of
proliferation and invasiveness for lung cancer. J Cancer Res Clin
Oncol. 137:1061–1070. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Blasberg JD, Goparaju CM, Pass HI and
Donington JS: Lung cancer osteopontin isoforms exhibit angiogenic
functional heterogeneity. J Thorac Cardiovasc Surg. 139:1587–1593.
2010. View Article : Google Scholar :
|
|
62
|
Nakamura KD, Tilli TM, Wanderley JL,
Palumbo A Jr, Mattos RM, Ferreira AC, Klumb CE4, Nasciutti LE and
Gimba ER: Osteopontin splice variants expression is involved on
docetaxel resistance in PC3 prostate cancer cells. Tumour Biol.
37:2655–2663. 2016. View Article : Google Scholar
|
|
63
|
Tilli TM, Bellahcène A, Castronovo V and
Gimba ER: Changes in the transcriptional profile in response to
overexpression of the osteopontin-c splice isoform in ovarian
(OvCar-3) and prostate (PC-3) cancer cell lines. BMC Cancer.
14:4332014. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Tilli TM, Mello KD, Ferreira LB, Matos AR,
Accioly MT, Faria PA, Bellahcène A, Castronovo V and Gimba ER: Both
osteopontin-c and osteopontin-b splicing isoforms exert
pro-tumorigenic roles in prostate cancer cells. Prostate.
72:1688–1699. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Lin J, Myers AL, Wang Z, Nancarrow DJ,
Ferrer-Torres D, Handlogten A, Leverenz K, Bao J, Thomas DG, Wang
TD, et al: Osteopontin (OPN/SPP1) isoforms collectively enhance
tumor cell invasion and dissemination in esophageal adenocarcinoma.
Oncotarget. 6:22239–22257. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Zhang MX, Xu YJ, Zhu MC and Yan F:
Overexpressed ostepontin-c as a potential biomarker for esophageal
squamous cell carcinoma. Asian Pac J Cancer Prev. 14:7315–7319.
2013. View Article : Google Scholar
|
|
67
|
Chae S, Jun HO, Lee EG, Yang SJ, Lee DC,
Jung JK, Park KC, Yeom YI and Kim KW: Osteopontin splice variants
differentially modulate the migratory activity of hepatocellular
carcinoma cell lines. Int J Oncol. 35:1409–1416. 2009.PubMed/NCBI
|
|
68
|
Takafuji V, Forgues M, Unsworth E,
Goldsmith P and Wang XW: An osteopontin fragment is essential for
tumor cell invasion in hepatocellular carcinoma. Oncogene.
26:6361–6371. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Tang X, Li J, Yu B, Su L, Yu Y, Yan M, Liu
B and Zhu Z: Osteopontin splice variants differentially exert
clinicopathological features and biological functions in gastric
cancer. Int J Biol Sci. 9:55–66. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Siddiqui AA, Jones E, Andrade D, Shah A,
Kowalski TE, Loren DE, Chipitsyna G and Arafat HA: Osteopontin
splice variant as a potential marker for metastatic disease in
pancreatic adenocarcinoma. J Gastroenterol Hepatol. 29:1321–1327.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Sarosiek K, Jones E, Chipitsyna G,
Al-Zoubi M, Kang C, Saxena S, Gandhi AV, Sendiky J, Yeo CJ and
Arafat HA: Osteopontin (OPN) isoforms, diabetes, obesity, and
cancer; what is one got to do with the other? A new role for OPN. J
Gastrointest Surg. 19:639–650. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Ferreira LB, Eloy C, Pestana A, Lyra J,
Moura M, Prazeres H, Tavares C, Sobrinho-Simões M, Gimba E and
Soares P: Osteopontin expression is correlated with differentiation
and good prognosis in medullary thyroid carcinoma. Eur J
Endocrinol. 174:551–561. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Ferreira LB, Tavares C, Pestana A, Pereira
CL, Eloy C, Pinto MT, Castro P, Batista R, Rios E, Sobrinho-Simões
M, et al: Osteopontin-a splice variant is overexpressed in
papillary thyroid carcinoma and modulates invasive behavior.
Oncotarget. 7:52003–52016. 2016.PubMed/NCBI
|
|
74
|
Yan W, Qian C, Zhao P, Zhang J, Shi L,
Qian J, Liu N, Fu Z, Kang C, Pu P, et al: Expression pattern of
osteopontin splice variants and its functions on cell apoptosis and
invasion in glioma cells. Neuro-oncol. 12:765–775. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Hahnel A, Wichmann H, Greither T, Kappler
M, Würl P, Kotzsch M, Taubert H, Vordermark D and Bache M:
Prognostic impact of mRNA levels of osteopontin splice variants in
soft tissue sarcoma patients. BMC Cancer. 12:1312012. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Inoue M and Shinohara ML: Intracellular
osteopontin (iOPN) and immunity. Immunol Res. 49:160–172. 2011.
View Article : Google Scholar
|
|
77
|
Shinohara ML, Kim HJ, Kim JH, Garcia VA
and Cantor H: Alternative translation of osteopontin generates
intracellular and secreted isoforms that mediate distinct
biological activities in dendritic cells. Proc Natl Acad Sci USA.
105:7235–7239. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Yushi Q, Li Z, Von Roemeling CA, Doeppler
H, Marlow LA, Kim BY, Radisky DC, Storz P, Copland JA and Tun HW:
Osteopontin is a multi-faceted pro-tumorigenic driver for central
nervous system lymphoma. Oncotarget. 7:32156–32171. 2016.PubMed/NCBI
|
|
79
|
Zohar R, Lee W, Arora P, Cheifetz S,
McCulloch C and Sodek J: Single cell analysis of intracellular
osteopontin in osteogenic cultures of fetal rat calvarial cells. J
Cell Physiol. 170:88–100. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Zhao W, Wang L, Zhang L, Yuan C, Kuo PC
and Gao C: Differential expression of intracellular and secreted
osteopontin isoforms by murine macrophages in response to toll-like
receptor agonists. J Biol Chem. 285:20452–20461. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Junaid A, Moon MC, Harding GE and Zahradka
P: Osteopontin localizes to the nucleus of 293 cells and associates
with polo-like kinase-1. Am J Physiol Cell Physiol. 292:C919–C926.
2007. View Article : Google Scholar
|
|
82
|
Zohar R, Suzuki N, Suzuki K, Arora P,
Glogauer M, McCulloch CA and Sodek J: Intracellular osteopontin is
an integral component of the CD44-ERM complex involved in cell
migration. J Cell Physiol. 184:118–130. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Shinohara ML, Lu L, Bu J, Werneck MB,
Kobayashi KS, Glimcher LH and Cantor H: Osteopontin expression is
essential for interferon-alpha production by plasmacytoid dendritic
cells. Nat Immunol. 7:498–506. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
84
|
Chen R, Crispin DA, Pan S, Hawley S,
McIntosh MW, May D, Anton-Culver H, Ziogas A, Bronner MP and
Brentnall TA: Pilot study of blood biomarker candidates for
detection of pancreatic cancer. Pancreas. 39:981–988. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Fedarko NS, Jain A, Karadag A, Van Eman MR
and Fisher LW: Elevated serum bone sialoprotein and osteopontin in
colon, breast, prostate, and lung cancer. Clin Cancer Res.
7:4060–4066. 2001.PubMed/NCBI
|
|
86
|
Collins AL, Rock J, Malhotra L, Frankel WL
and Bloomston M: Osteopontin expression is associated with improved
survival in patients with pancreatic adenocarcinoma. Ann Surg
Oncol. 19:2673–2678. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Ashkar S, Weber GF, Panoutsakopoulou V,
Sanchirico ME, Jansson M, Zawaideh S, Rittling SR, Denhardt DT,
Glimcher MJ and Cantor H: Eta-1 (osteopontin): an early component
of type-1 (cell-mediated) immunity. Science. 287:860–864. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Chan SC, Tekari A, Benneker LM, Heini PF
and Gantenbein B: Osteogenic differentiation of bone marrow stromal
cells is hindered by the presence of intervertebral disc cells.
Arthritis Res Ther. 18:292015. View Article : Google Scholar
|
|
89
|
Kumar S, Sharma P, Kumar D, Chakraborty G,
Gorain M and Kundu GC: Functional characterization of stromal
osteopontin in melanoma progression and metastasis. PLoS One.
8:e691162013. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Chen JJ, Lin YC, Yao PL, Yuan A, Chen HY,
Shun CT, Tsai MF, Chen CH and Yang PC: Tumor-associated
macrophages: the double-edged sword in cancer progression. J Clin
Oncol. 23:953–964. 2005. View Article : Google Scholar
|
|
91
|
Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang
W, Xiong YQ, Wu WZ, Wang L, Tang ZY and Sun HC: High expression of
macrophage colony-stimulating factor in peritumoral liver tissue is
associated with poor survival after curative resection of
hepatocellular carcinoma. J Clin Oncol. 26:2707–2716. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Wai PY, Guo L, Gao C, Mi Z, Guo H and Kuo
PC: Osteopontin inhibits macrophage nitric oxide synthesis to
enhance tumor proliferation. Surgery. 140:132–140. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Sato K, Iwai A, Nakayama Y, Morimoto J,
Takada A, Maruyama M, Kida H, Uede T and Miyazaki T: Osteopontin is
critical to determine symptom severity of influenza through the
regulation of NK cell population. Biochem Biophys Res Commun.
417:274–279. 2012. View Article : Google Scholar
|
|
94
|
Collighan RJ and Griffin M:
Transglutaminase 2 cross-linking of matrix proteins: biological
significance and medical applications. Amino Acids. 36:659–670.
2009. View Article : Google Scholar
|
|
95
|
He B, Mirza M and Weber GF: An osteopontin
splice variant induces anchorage independence in human breast
cancer cells. Oncogene. 25:2192–2202. 2006. View Article : Google Scholar
|
|
96
|
Shen H and Weber GF: The osteopontin-c
splice junction is important for anchorage-independent growth. Mol
Carcinog. 53:480–487. 2014. View Article : Google Scholar
|
|
97
|
Shi Z, Wang B, Chihanga T, Kennedy MA and
Weber GF: Energy metabolism during anchorage-independence.
Induction by osteopontin-c. PLoS One. 9:e1056752014. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Sivakumar S and Niranjali Devaraj S:
Tertiary structure prediction and identification of druggable
pocket in the cancer biomarker - osteopontin-c. J Diabetes Metab
Disord. 13:132014. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Mi Z, Oliver T, Guo H, Gao C and Kuo PC:
Thrombin-cleaved COOH(−) terminal osteopontin peptide binds with
cyclophilin C to CD147 in murine breast cancer cells. Cancer Res.
67:4088–4097. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Chimparlee N, Chuaypen N, Khlaiphuengsin
A, Pinjaroen N, Payungporn S, Poovorawan Y and Tangkijvanich P:
Diagnostic and prognostic roles of serum osteopontin and
osteopontin promoter polymorphisms in hepatitis B-related
hepatocellular carcinoma. Asian Pac J Cancer Prev. 16:7211–7217.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Sharma A, Hong S, Singh R and Jang J:
Single-walled carbon nanotube based transparent immunosensor for
detection of a prostate cancer biomarker osteopontin. Anal Chim
Acta. 869:68–73. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Faria M, Halquist MS, Yuan M, Mylott W Jr,
Jenkins RG and Karnes HT: Comparison of a stable isotope labeled
(SIL) peptide and an extended SIL peptide as internal standards to
track digestion variability of an unstable signature peptide during
quantification of a cancer biomarker, human osteopontin, from
plasma using capillary microflow LC-MS/MS. J Chromatogr B Analyt
Technol Biomed Life Sci. 1001:156–168. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Meirinho SG, Dias LG, Peres AM and
Rodrigues LR: Development of an electrochemical RNA-aptasensor to
detect human osteopontin. Biosens Bioelectron. 71:332–341. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Chen H, Mei Q, Jia S, Koh K, Wang K and
Liu X: High specific detection of osteopontin using a
three-dimensional copolymer layer support based on electrochemical
impedance spectroscopy. Analyst (Lond). 139:4476–4481. 2014.
View Article : Google Scholar
|
